TABLE 2.

Cytotoxicity of new imidazole-based N-phenylbenzamide derivatives 4a–j.

Test compound	IC50 value in µM (mean ± SD) a
	A549	HeLa	MCF-7
4a	23.1 ± 0.12	36.4 ± 0.28	23.5 ± 0.15
4b	20.9 ± 0.36	16.4 ± 0.32	19.1 ± 0.26
4c	>100	55.6 ± 0.44	73.2 ± 0.39
4d	14.7 ± 0.22	12.1 ± 0.16	14.6 ± 0.24
4e	8.9 ± 0.17	11.1 ± 0.15	9.2 ± 0.12
4f	7.5 ± 0.38	9.3 ± 0.11	8.9 ± 0.11
4g	13.4 ± 0.14	45.3 ± 0.39	22.3 ± 0.26
4h	10.7 ± 0.13	11.9 ± 0.12	9.3 ± 0.37
4i	16.9 ± 0.25	13.1 ± 0.27	11.6 ± 0.15
4j	>100	>100	69.5 ± 0.46
Dox	0.8 ± 0.05	0.7 ± 0.06	0.9 ± 0.08

^aExperiments were carried out in triplicates. Doxorubicin (Dox) was used as a positive control.